Skip to main content
. Author manuscript; available in PMC: 2020 Dec 14.
Published in final edited form as: Infect Disord Drug Targets. 2018;18(3):224–232. doi: 10.2174/1871526518666180521091158

Fig. (2).

Fig. (2).

Protein purification scheme. A) Schematic diagram of the purification process for Minerva virus protease. B) Uninduced and induced cells as well as cell lysate fractions and the 1st Ni2+ affinity column load, flow-through, and wash. C) 1st Ni2+ affinity column eluted fractions containing the His6-SUMO-MVpro fusion protein. D) Steps 2 and 3 of scheme A): after cleavage with ULP-1, MVpro appears at a MW of ~20 kDa. MVpro is eluted in the flow-through of the 2nd Ni2+ affinity column. SE = size exclusion column load. Panels B)-D) are 15% SDS-PAGE gels stained with coomassie blue. (The color version of the figure is available in the electronic copy of the article).